This Breast Cancer Clinical Trial Needs Black Women to Ensure Our Survival – BlackDoctor.org [Video]

For Black women living with estrogen receptor-positive (ER+) metastatic breast cancer, a new clinical trial offers hope in the quest to overcome treatment resistance and extend survival. The VIKTORIA-1 trial is evaluating a potentially groundbreaking drug called gedatolisib, nicknamed “Get It All,” for its ability to inhibit the PI3K/AKT/mTOR pathway implicated in many cases of endocrine therapy resistance.

What exactly is the VIKTORIA-1 trial?

Dr. Mike Danso, a medical oncologist specializing in breast cancer clinical trials, explains the significance of this study to BDO in a Facebook town hall: “Preliminary data looking at this particular drug using VIKTORIA-1 called gedatolisib…has shown to be very efficacious in patients with or without PIK mutations.” The PI3K/AKT/mTOR pathway, often referred to as the “PAM pathway,” plays a major role in up to 40 percent of ER+ metastatic breast cancers.

The trial aims to incorporate gedatolisib into the standard of care for patients who have progressed on first-line therapies like CDK4/6 inhibitors (Ibrance, Kisqali, …